The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized P3 open label multicenter two arm study comparing the efficacy of MEK162 vs Dacarbazine in patients with previously untreated advanced
|Effective start/end date
|2/28/13 → 3/31/16
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.